Explore the words cloud of the LiveRest project. It provides you a very rough idea of what is the project "LiveRest" about.
The following table provides information about the project.
|Coordinator Country||Denmark [DK]|
|Total cost||2˙016˙546 €|
|EC max contribution||1˙411˙582 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2018-11-01 to 2020-10-31|
Take a look of project's partnership.
85% of Spinal Cord Injury (SCI) patients will develop a Pressure Injury (PI), and 8% of them will die due to associated complications. PI treatment costs €20 billion per year to the European Public Health System (EPHS), uses a lot of resources (e.g. caregivers and hospital beds) and causes injuries to the caregivers that perform repositioning of the patients, resulting in compensation costs and extra human resource reduction. PI are preventable, however 38% of PI appear using current commercial prevention devices because PI risk assessment is only based on pressure instead of Tissue Viability (TV) which also takes into account user status and context. The aim of this project is to demonstrate in operational environment, produce and commercialise in the Assistive Technology market LiveRest system, a disruptive ICT solution that is able to avoid the development of PI, being the only device on the market that clinically demonstrates PI prevention. LiveRest will be embedded on a personalised wheelchair, and its novelties are: a) to measure PI risk in real time based on TV with impedance, pressure, temperature and humidity textile sensors; b) to decide the best combination of PI prevention strategies based on risk, user and context; and c) to perform the selected strategy based on combined actuation systems. LiveRest is aligned with key EU global challenges: disability, independent living, job inclusion, reduction of social and health care costs, and increase of labour. Target customers are SCI patients and hospitals. Benefits for the patients are increased sitting time and enhanced health, social inclusion, independent living and ageing well. EPHS savings will result in more than €40 million per year, plus avoid loss of medical resources. During Phase 2, we will achieve the free marketability of LiveRest, demonstrate the system in operational environment and elaborate an investor-ready business plan, including commercialisation and mass-production strategies.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIVEREST" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LIVEREST" are provided by the European Opendata Portal: CORDIS opendata.
MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINERead More
Pole climbing solution to improve safety at work and to prevent fatal accidents in industrial climbingRead More
Opening new markets for Single Quantum PhotodetectorsRead More